Accurate prediction on clopidogrel's abnormal behaviors and pharmacobehavioral economics

Summary

Thirteen years ago, under asymmetrical conditions, by analyzing the abnormal economic behavior and game process of clopidogrel after marketing, based on behavioral economics theory, we predicted that there were problems with the results of Phase III CAPRIE trial. Three years later, direct evidence was found in CAPRIE's Table 6. The vital data for fatal events in many groups, and nyrs in all subgroups, were unbalanced and illogical. CAPRIE's results were wrong, and clopidogrel could not be superior to aspirin. Wrong data, noise trading, companion effect, herd behavior, butterfly effect, etc. have led Clopidogrel's global sales to exceed $90 billion. We proposed modifying the guidelines for clopidogrel, medical statistical theory, and constructing new disciplines such as pharmacobehavioral, medical behavioral, health behavioral economics, etc. Although our empirical study revealed negative information, we found that only a few drugs caused changes in medical behavior, resulting in economic growth of more than $826.5 billion.[ The latest modified and updated version is: Version 7; Li Liu1*, FanDian Zeng2, XiaoYan Yang2. (2022). Accurate prediction on clopidogrel's abnormal behaviors and pharmacobehavioral economics. Zenodo. https://doi.org/10.5281/zenodo.7995680]